Understanding DIR and Pharmacy Value-Based Contracting

01/27/22 • 14 min

Pharmacy DIR (direct and indirect remuneration) is a value-based tool that’s getting a lot of buzz on Capitol Hill and at CMS. To better understand Pharmacy DIR and how it affects Medicare beneficiaries, JC Scott talks with Dr. William Fleming, Segment President of Pharmacy Solutions and Chief Corporate Affairs Officer for Humana, Inc.

Dr. Fleming explains what pharmacy direct and indirect remuneration (DIR) means for pharmacists, why it should be thought of as value-based contracting, and how it engages with the pharmacist community to increase medication adherence and keep pharmacies accountable for increasing quality for patients.

Previous Episode

PBM Transparency

JC Scott talks with Julie Goon, Senior Vice President of Public Affairs for Anthem, Inc., and Tim Dube, PCMA’s Vice President of Regulatory Affairs. Together, they discuss good versus bad transparency, how transparency has evolved in healthcare, how it can empower the consumer to have more control over the prices they pay through evolved technology, and which transparency rules decrease prescription drug prices, and which rules actually increase prices.

Next Episode

Importance of PBMs in Health Care Costs

This episode highlights the important role that PBMs play in lowering prescription drug costs amid the Federal Trade Commission’s (FTC) recent interest in conducting a PBM study. The episode features Ross Margulies, a Partner with the law firm Foley Hoag. Mr. Margulies outlines the role that PBMs play in Medicare, and how PBM tools and technology are working to lower drug costs for patients as well as improving their pharmacy experience.